COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Read our FAQs.

Assessment of the WATCHMANTM Device in Patients Unsuitable for Oral Anticoagulation ASAP-TOO

Trial ID:
Matthew Price
The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.

Inclusion Criteria: - The subject is of legal age to participate in the study per the laws of their respective geography. - The subject has documented paroxysmal, persistent, permanent or long-term/longstanding persistent non-valvular atrial fibrillation (i.e., the subject has not been diagnosed with rheumatic mitral valvular heart disease). - The subject has a calculated CHA2DS2-VASc score of 2 or greater. - The subject is deemed by two study physicians to be unsuitable for oral anticoagulation. - The subject is deemed by a study physician to be suitable for the defined protocol pharmacologic regimen of aspirin and clopidogrel therapy following WATCHMAN Closure Device implant. - The subject or legal representative is able to understand and willing to provide written informed consent to participate in the trial. - The subject is able and willing to return for required follow-up visits and examinations. Exclusion Criteria: - The subject is unable or unwilling to return for required follow-up visits and examinations. - The subject had or is planning to have any invasive cardiac procedure within 30 days prior to randomization (e.g., cardioversion, ablation). - The subject is planning to have any cardiac or non-cardiac invasive or surgical procedure that would necessitate stopping or modifying the protocol required medication regimen within 90 days after the WATCHMAN Closure Device implant (e.g., cardioversion, ablation, cataract surgery). - The subject had a prior stroke (of any cause) or TIA within the 30 days prior to randomization. - The subject had a prior BARC type 3 or 4 bleeding event within the 14 days prior to randomization. Lack of resolution of related clinical sequelae, or planned and pending interventions to resolve bleeding/bleeding source, are a further exclusion regardless of timing of the bleeding event. - The subject has a history of atrial septal repair or has an ASD/PFO device. - The subject has an implanted mechanical valve prosthesis in any position. - The subject suffers from New York Heart Association Class IV Congestive Heart Failure. - The subject has LVEF < 30%. - The subject is of childbearing potential and is, or plans to become pregnant during the time of the study (method of assessment upon study physician's discretion). - The subject is currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance should be brought to the attention of the sponsor to determine eligibility. - The subject has a life expectancy of less than two years. - The subject has a known or suspected hypercoagulable state.

Why isn't this trial accepting new patients?

The trial may have a limited enrollment number, reached its maximum, or come to the end of its enrollment period. View trials that are recruiting

How else can Scripps help me?

We have a broad range of physician expertise and specialized medical services available. You can find a doctor online, call 1-800-SCRIPPS (1-800-727-4777) for personal help, or see related Scripps services.

How can I find trials that are accepting new participants?

For more information, see a list of trials that are recruiting, or call the clinical research office at 858-648-6402 for help.